Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ®Funding will support clinical trials in vulnerable groups, such as children and pregnant women Partnership will also support technology transfer to an additional manufacturer to supply IXCHIQ® to Asian LMICsIXCHIQ® is already approved for use in adults 18 years of age and older in the U.S., Canada and Europe Oslo, Norway, and Saint-Herblain, France, July 22, 2024—The Coalition for Epidemi ...